View ValuationBonesupport Holding 향후 성장Future 기준 점검 6/6Bonesupport Holding (는) 각각 연간 33.8% 및 23.2% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 45.8% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 35.9% 로 예상됩니다.핵심 정보33.8%이익 성장률45.82%EPS 성장률Biotechs 이익 성장21.9%매출 성장률23.2%향후 자기자본이익률35.93%애널리스트 커버리지Good마지막 업데이트27 May 2026최근 향후 성장 업데이트공시 • Jan 14Bonesupport Holding AB (Publ) Provides Earnings Guidance for the Fourth Quarter of 2025 and Full Year 2026Bonesupport Holding AB (publ) provided earnings guidance for the fourth quarter of 2025 and full year 2026. For the quarter, Net sales is expected to total 313 MSEK, representing 36.0% growth at constant exchange rates compared with the same period in 2024. For the year, the company expected sales growth above 35% at constant exchange rates.공시 • Nov 29Bonesupport Holding AB Provides Sales Guidance for the Year 2024Bonesupport Holding AB provided sales guidance for the year 2024. For the year, the company expects sales growth to be above 40% (in constant currency).Breakeven Date Change • Jun 02Forecast breakeven date moved forward to 2023The 2 analysts covering Bonesupport Holding previously expected the company to break even in 2024. New consensus forecast suggests the company will make a profit of kr15.7m in 2023. Earnings growth of 103% is required to achieve expected profit on schedule.Breakeven Date Change • May 15Forecast breakeven date moved forward to 2023The 2 analysts covering Bonesupport Holding previously expected the company to break even in 2024. New consensus forecast suggests the company will make a profit of kr15.7m in 2023. Earnings growth of 103% is required to achieve expected profit on schedule.Breakeven Date Change • Oct 25Forecast to breakeven in 2023The 2 analysts covering Bonesupport Holding expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 21% to 2022. The company is expected to make a profit of kr5.67m in 2023. Average annual earnings growth of 120% is required to achieve expected profit on schedule.Breakeven Date Change • Jun 01Forecast breakeven date moved forward to 2023The 2 analysts covering Bonesupport Holding previously expected the company to break even in 2024. New consensus forecast suggests losses will reduce by 26% to 2022. The company is expected to make a profit of kr2.70m in 2023. Average annual earnings growth of 112% is required to achieve expected profit on schedule.모든 업데이트 보기Recent updates공시 • Jun 16Bonesupport Holding AB (publ) (OM:BONEX) commences an Equity Buyback Plan for own shares, under the authorization approved on May 12, 2026.Bonesupport Holding AB (publ) (OM:BONEX) commences share repurchases on June 9, 2026, under the program mandated by the shareholders in the Annual General Meeting held on May 12, 2026. As per the mandate, the company is authorized to repurchase own shares, representing does not exceed 10% of its issued share capital at any point of time. The shares will be repurchased at a price which falls within the prevailing price interval registered at each point in time (i.e. in the interval between the highest purchase price and the lowest selling price). The purpose of the proposed authorizations, and the reason for deviating from the shareholders' preferential rights with regard to transfer of own shares, is to enable acquisition financing through the utilization of own ordinary shares, to give the Board of Directors the opportunity to continuously adapt the company's capital structure to the company's capital needs and thereby contribute to increased shareholder value, and to give the company the opportunity to divest shares in its own holding for cash flow hedging of social security costs arising from the delivery of shares to participants in the incentive program resolved by the Annual General Meeting 2023 (LTI 2023).The ordinary shares shall be made in cash. The repurchased shares will be cancelled by resolution of upcoming Annual General Meetings. The program is valid until the next Annual General Meeting in 2027. On June 8, 2026, the company announced a share repurchase program. Under the program, the company will repurchase up to 373,320 shares for SEK 100 million. The ordinary shares shall be made in cash. The program will commence from June 9, 2026 and be valid till July 9, 2026.Recent Insider Transactions • Jun 02Director recently bought kr200k worth of stockOn the 27th of May, Jens Viebke bought around 844 shares on-market at roughly kr237 per share. This transaction amounted to 39% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth kr346k. Despite this recent purchase, insiders have collectively sold kr6.4m more in shares than they bought in the last 12 months.공시 • Jan 14Bonesupport Holding AB (Publ) Provides Earnings Guidance for the Fourth Quarter of 2025 and Full Year 2026Bonesupport Holding AB (publ) provided earnings guidance for the fourth quarter of 2025 and full year 2026. For the quarter, Net sales is expected to total 313 MSEK, representing 36.0% growth at constant exchange rates compared with the same period in 2024. For the year, the company expected sales growth above 35% at constant exchange rates.공시 • Oct 23+ 3 more updatesBonesupport Holding AB (publ) to Report Q1, 2026 Results on Apr 22, 2026Bonesupport Holding AB (publ) announced that they will report Q1, 2026 results on Apr 22, 2026공시 • Sep 16Bonesuport Announces Positive Results from A Clinical Study Demonstrating Significantly Improved Patient-Based Outcomes for Cerament®? G in Single-Stage Revision Surgery for Patients Patients Lining from Periprosthetic Joint InfectionBonesuport announced positive results from a clinical study demonstrating significantly improved patient-reported outcomes for CERAMENT®? G in single-stage revision surgery for patients suffering from periprosthetic joint infection (PJI) of the hip. The top-line results were presented at the European Bone and Joint Infection Society (EBJIS) annual meting, 11-13 September 2025. The prospective clinical study conducted at Charite - Universitatsmedizin Berlin, involved twenty patients with confirmed PJI of the hip. The procedure included implant removal, debridement (removal of infected tissue), and defect augmentation using CERAMENT G, followed by cementless revision arthroplasty in a single stage procedure. None of the patients experienced a re-infection during the 24-month follow-up period. Significant improvements were observed in patient-reported outcomes eg. the Harris Hip Score, EQ-5D-5L and Pain Visual Analogue Scale (VAS). According to the German Arthroplasty Registry (Endoprothesenregister Deutschland) the risk of reinfection is 30% within two years following hip revision surgery. The current standard of care remains a two-stage procedure, where the infection is treated in a primary surgery and the new prosthesis is implanted in a second surgery up to eight weeks later. The study (CeraHip) is expected to be published during the autumn.공시 • Apr 24Bonesupport Holding AB (publ), Annual General Meeting, May 27, 2025Bonesupport Holding AB (publ), Annual General Meeting, May 27, 2025, at 10:00 W. Europe Standard Time. Location: to be held at elite hotel ideon, scheelevagen 27, lund Sweden공시 • Apr 01Bonesupport Holding AB (Publ) Files FDA Submission for Cerament VBonesUPPORT announced that the company has submitted market authorization application for its antibiotic eluting bone graft substitute, CERAMENT® V (vancomycin), with the Food and Drug Administration (FDA), for the indication bone infection. The market approval for CERAMENT® G in 2022 was based on extensive efficacy and patient safety data, with nearly 17,000 clinical data points. The clinical data, from several published studies, demonstrated that CERAMENT G is superior to previous standard options in managing bone infections. With market authorization for CERAMENT V, physicians would be equipped with an additional tool to manage bone infections, primarily caused by Methicillin-Resistant Staphylococcus eg. MRSA or MRSE. CERAMENT V in Europe, where the product has had market approval for several years, represents 15% of the sales of antibiotic-releasing products. Bone grafts with local antibiotic release have proven to be a very important tool in the ambition to drastically reduce the need for systemic antibiotic use and combat antibiotic resistance. CERAMENT V has previously received the categorization of "breakthrough device" for the indication of bone infection from the FDA.공시 • Jan 08Bonesupport Holding AB (publ) Announces Study Results for CERAMENT G and CERAMENT V in Surgical Treatment of Bone Infection Due to Diabetic Foot UlcersBonesupport Holding AB (publ) announced strong study results for CERAMENT G and CERAMENT V in the surgical treatment of bone infection due to diabetic foot ulcers. The study is the first to document that surgical treatment with antibiotic eluting CERAMENT has contributed to increased survival rates over a 5-year period. The published clinical study included 105 patients with diabetic foot osteomyelitis that were either treated with surgical conventional treatment or surgical treatment including CERAMENT G or CERAMENT V. The results regarding infection healing, residual infection, re-infection, amputation, and mortality all showed significant advantages for the antibiotic eluting CERAMENT compared to standard treatment. The pioneering finding of the study was the dramatic improvement in 5-year survival within the CERAMENT group: 87.5%, compared to 44.9% in the standard treatment group [Mortality rate 12,5%, versus 55.1%, p<0.00001].공시 • Nov 29Bonesupport Holding AB (publ) Announces Nomination Committee ChangesThe composition of BONESUPPORT's Nomination Committee ahead of the 2025 Annual General Meeting was announced in the company's interim report for the third quarter on October 24 2024. As a result of a subsequent change in ownership, the composition of the Nomination Committee has changed with Anna Sundberg (appointed by Handelsbanken Fonder) leaving the Nomination Committee and Erik Selin (appointed by Erik Selin Fastigheter AB) joining as a new member of the Nomination Committee. Accordingly, the Nomination Committee ahead of the 2025 Annual General Meeting consists of the following members: Caroline Sjösten, appointed by Swedbank Robur Fonder; Erik Selin, appointed by Erik Selin Fastigheter; and Staffan Lindstrand, appointed by HealthCap. In addition, the Chairman of the Board of BONESUPPORT, Lennart Johansson, is co-opted to the Nomination Committee. The Nomination Committee has appointed Caroline Sjösten as Committee chair.공시 • Oct 31Erik Selin acquired 5.92% stake in Bonesupport Holding AB (publ) (OM:BONEX) from Odlander, Fredrikson & Co. AB.Erik Selin acquired 5.92% stake in Bonesupport Holding AB (publ) (OM:BONEX) from Odlander, Fredrikson & Co. AB for SEK 1.3 billion on October 30, 2024. In this transaction, Erik Selin will acquire 3.9 million shares at a rate of SEK 325. Erik Selin acquired 5.92% stake in Bonesupport Holding AB (publ) (OM:BONEX) from Odlander, Fredrikson & Co. AB on October 30, 2024.공시 • Oct 26+ 3 more updatesBonesupport Holding AB (publ) to Report Q2, 2025 Results on Jul 15, 2025Bonesupport Holding AB (publ) announced that they will report Q2, 2025 results on Jul 15, 2025공시 • Jun 13+ 1 more updateBonesupport Holding AB (Publ) Appoints Anna Stegmark as EVP Quality Management & Regulatory Affairs, with Effect from 1 July 2024Bonesupport Holding AB (publ) announced that Anna Stegmark has been appointed EVP Quality Management & Regulatory Affairs with effect from 1 July 2024. She will also be part of the management team. Anna Stegmark's professional career comprises more than 19 years in the medical device sector, leading global quality and regulatory teams since 2010. Most recently, she was with Radiometer Medical as Director QA Operation.Reported Earnings • Apr 23Full year 2023 earnings released: EPS: kr3.77 (vs kr1.06 loss in FY 2022)Full year 2023 results: EPS: kr3.77 (up from kr1.06 loss in FY 2022). Revenue: kr591.1m (up 80% from FY 2022). Net income: kr245.0m (up kr313.2m from FY 2022). Profit margin: 42% (up from net loss in FY 2022). The move to profitability was primarily driven by higher revenue. Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 24% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 89% per year but the company’s share price has only increased by 60% per year, which means it is significantly lagging earnings growth.공시 • Feb 23Bonesupport Holding AB (Publ) Announces Resignation of Kristina Ingvar as Executive Vice President Quality Management & Regulatory AffairsBONESUPPORT AB announced a change in its management team. Kristina Ingvar will leave BONESUPPORT and her role as Executive Vice President Quality Management & Regulatory Affairs (EVP QM&RA). The change is effective as per 22 March 2024. She will take up a position as Corporate Vice President in the global healthcare company Novo Nordisk. Recruitment for the position EVP QM&RA has been initiated.Reported Earnings • Feb 17Full year 2023 earnings released: EPS: kr3.77 (vs kr1.06 loss in FY 2022)Full year 2023 results: EPS: kr3.77 (up from kr1.06 loss in FY 2022). Revenue: kr591.1m (up 80% from FY 2022). Net income: kr245.0m (up kr313.2m from FY 2022). Profit margin: 42% (up from net loss in FY 2022). The move to profitability was primarily driven by higher revenue. Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 89% per year but the company’s share price has only increased by 37% per year, which means it is significantly lagging earnings growth.공시 • Nov 29Bonesupport Holding AB Provides Sales Guidance for the Year 2024Bonesupport Holding AB provided sales guidance for the year 2024. For the year, the company expects sales growth to be above 40% (in constant currency).공시 • Oct 27+ 4 more updatesBonesupport Holding AB (publ) to Report Q1, 2024 Results on Apr 25, 2024Bonesupport Holding AB (publ) announced that they will report Q1, 2024 results on Apr 25, 2024공시 • Oct 17Bone Support Receives “Breakthrough Device Designation” for Cerament® V for the Indication of Bone InfectionBONESUPPORTTM announced that the company's antibiotic eluting product CERAMENT® V has received categorization as a "breakthrough device" for the indication bone infection by the American Food and Drug Administration (FDA). The categorization breakthrough device is assigned to products that are considered to provide a more effective treatment of severe medical conditions, where there is no comparable equivalent on the market. The categorization has been added to expedite the regulatory review of new medical devices and give patients faster access to new treatment options. CERAMENT® G has previously received breakthrough device designation for the indication's bone infection and trauma.Recent Insider Transactions • Jul 17Insider recently bought kr426k worth of stockOn the 14th of July, Michael Mortensen bought around 3k shares on-market at roughly kr142 per share. This transaction amounted to 30% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth kr604k. Despite this recent purchase, insiders have collectively sold kr44m more in shares than they bought in the last 12 months.Reported Earnings • Jul 14Second quarter 2023 earnings released: EPS: kr0.08 (vs kr0.25 loss in 2Q 2022)Second quarter 2023 results: EPS: kr0.08 (up from kr0.25 loss in 2Q 2022). Revenue: kr140.4m (up 88% from 2Q 2022). Net income: kr5.21m (up kr21.5m from 2Q 2022). Profit margin: 3.7% (up from net loss in 2Q 2022). The move to profitability was driven by higher revenue. Revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 36% per year whereas the company’s share price has increased by 39% per year.Breakeven Date Change • Jun 02Forecast breakeven date moved forward to 2023The 2 analysts covering Bonesupport Holding previously expected the company to break even in 2024. New consensus forecast suggests the company will make a profit of kr15.7m in 2023. Earnings growth of 103% is required to achieve expected profit on schedule.공시 • May 26BONESUPPORT Holding AB Announces Strong Long-Term Results with CERAMENT®G for Severe Open FracturesBONESUPPORT Holding AB announced the recent publication of long-term follow-up data demonstrating sustained high limb salvage rates and low deep infection rates with the company's antibiotic-eluting bone graft CERAMENT G. The study of 81 patients were managed with a single-stage procedure with CERAMENT G. Patients arrived at hospital with significant tissue loss and exposed bone tissue. With a mean follow-up of 55.8 months after surgery, it was found that 96.3% of patients had avoided an amputation, 96% had achieved bony union within 12 months, and 96.3% had avoided deep infection. The patients from the study were classified as having one of the most severe categories of open fractures (Gustilo-Anderson class IIIB), usually caused by traffic accidents. For this patient population, earlier publications have shown up to 16% amputation rates, non-unions up to 29%, and deep infection rates as high as 52%.Recent Insider Transactions • May 18Insider recently sold kr701k worth of stockOn the 12th of May, Annelie Vikner sold around 7k shares on-market at roughly kr108 per share. This transaction amounted to 20% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth kr15m. Insiders have been net sellers, collectively disposing of kr43m more than they bought in the last 12 months.Breakeven Date Change • May 15Forecast breakeven date moved forward to 2023The 2 analysts covering Bonesupport Holding previously expected the company to break even in 2024. New consensus forecast suggests the company will make a profit of kr15.7m in 2023. Earnings growth of 103% is required to achieve expected profit on schedule.Recent Insider Transactions • May 05Chief Executive Officer recently sold kr15m worth of stockOn the 28th of April, Emil Billbäck sold around 146k shares on-market at roughly kr100 per share. This transaction amounted to 19% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Emil has been a net seller over the last 12 months, reducing personal holdings by kr21m.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Director Christine Rankin was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Apr 24Full year 2022 earnings released: kr1.06 loss per share (vs kr1.34 loss in FY 2021)Full year 2022 results: kr1.06 loss per share (improved from kr1.34 loss in FY 2021). Revenue: kr328.8m (up 55% from FY 2021). Net loss: kr68.2m (loss narrowed 20% from FY 2021). Revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 37% per year and the company’s share price has also increased by 37% per year.Recent Insider Transactions • Mar 18Insider recently sold kr1.4m worth of stockOn the 14th of March, Fergus MacLeod sold around 17k shares on-market at roughly kr79.03 per share. This transaction amounted to 30% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of kr22m more than they bought in the last 12 months.Reported Earnings • Feb 18Full year 2022 earnings released: kr1.06 loss per share (vs kr1.34 loss in FY 2021)Full year 2022 results: kr1.06 loss per share (improved from kr1.34 loss in FY 2021). Revenue: kr328.8m (up 55% from FY 2021). Net loss: kr68.2m (loss narrowed 20% from FY 2021). Revenue is forecast to grow 32% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 38% per year whereas the company’s share price has increased by 35% per year.Board Change • Feb 09No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Director Christine Rankin was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Jan 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Director Christine Rankin was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Recent Insider Transactions • Jan 01Director recently bought kr203k worth of stockOn the 28th of December, Mary O’Connor bought around 3k shares on-market at roughly kr80.33 per share. This transaction amounted to 85% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold kr21m more in shares than they bought in the last 12 months.Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Director Christine Rankin was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.공시 • Oct 30+ 2 more updatesBonesupport Holding AB (publ) to Report Q3, 2023 Results on Oct 26, 2023Bonesupport Holding AB (publ) announced that they will report Q3, 2023 results on Oct 26, 2023Reported Earnings • Oct 28Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: kr84.6m (up 54% from 3Q 2021). Net loss: kr15.0m (loss widened 6.3% from 3Q 2021). Revenue is forecast to grow 36% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the United Kingdom.Breakeven Date Change • Oct 25Forecast to breakeven in 2023The 2 analysts covering Bonesupport Holding expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 21% to 2022. The company is expected to make a profit of kr5.67m in 2023. Average annual earnings growth of 120% is required to achieve expected profit on schedule.Board Change • Oct 03No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Director Christine Rankin was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Sep 13No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Director Christine Rankin was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Jul 29No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Director Christine Rankin was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Jul 15Second quarter 2022 earnings released: kr0.25 loss per share (vs kr0.42 loss in 2Q 2021)Second quarter 2022 results: kr0.25 loss per share (up from kr0.42 loss in 2Q 2021). Revenue: kr74.6m (up 44% from 2Q 2021). Net loss: kr16.3m (loss narrowed 40% from 2Q 2021). Over the next year, revenue is forecast to grow 37%, compared to a 11% growth forecast for the industry in the United Kingdom.Recent Insider Transactions • Jun 14Insider recently bought kr101k worth of stockOn the 8th of June, Lars Lindgren bought around 2k shares on-market at roughly kr63.00 per share. In the last 3 months, there was an even bigger purchase from another insider worth kr1.2m. Insiders have collectively bought kr4.0m more in shares than they have sold in the last 12 months.Breakeven Date Change • Jun 01Forecast breakeven date moved forward to 2023The 2 analysts covering Bonesupport Holding previously expected the company to break even in 2024. New consensus forecast suggests losses will reduce by 26% to 2022. The company is expected to make a profit of kr2.70m in 2023. Average annual earnings growth of 112% is required to achieve expected profit on schedule.Board Change • May 31Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. 1 independent director (4 non-independent directors). Independent Director Tone Kvale was the last independent director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Breakeven Date Change • Feb 20Forecast breakeven date pushed back to 2024The 2 analysts covering Bonesupport Holding previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 34% per year to 2023. The company is expected to make a profit of kr135.5m in 2024. Average annual earnings growth of 71% is required to achieve expected profit on schedule.Reported Earnings • Feb 18Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: kr1.31 loss per share (up from kr1.72 loss in FY 2020). Revenue: kr212.9m (up 18% from FY 2020). Net loss: kr85.5m (loss narrowed 16% from FY 2020). Revenue missed analyst estimates by 1.1%. Over the next year, revenue is forecast to grow 42%, compared to a 16% growth forecast for the pharmaceuticals industry in the United Kingdom.Board Change • Feb 01Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. 1 independent director (4 non-independent directors). Independent Director Tone Kvale was the last independent director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Dec 15Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. 1 independent director (4 non-independent directors). Independent Director Tone Kvale was the last independent director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Nov 06Third quarter 2021 earnings releasedThe company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: kr54.9m (up 14% from 3Q 2020). Net loss: kr14.1m (loss narrowed 34% from 3Q 2020).Breakeven Date Change • Nov 02Forecast to breakeven in 2023The 2 analysts covering Bonesupport Holding expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr83.0m in 2023. Average annual earnings growth of 72% is required to achieve expected profit on schedule.Board Change • Nov 02Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Director Tone Kvale was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Recent Insider Transactions • Aug 14Chief Financial Officer recently bought kr87k worth of stockOn the 11th of August, Håkan Johansson bought around 1k shares on-market at roughly kr74.15 per share. In the last 3 months, there was an even bigger purchase from another insider worth kr1.6m. Håkan has been a buyer over the last 12 months, purchasing a net total of kr521k worth in shares.Board Change • Aug 03Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Director Tone Kvale was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Recent Insider Transactions • Aug 03Executive VP of R&D recently sold kr595k worth of stockOn the 29th of July, Michael Diefenbeck sold around 8k shares on-market at roughly kr78.25 per share. This was the largest sale by an insider in the last 3 months. Despite this recent sale, insiders have collectively bought kr2.4m more than they sold in the last 12 months.Recent Insider Transactions • May 22Chief Financial Officer recently bought kr210k worth of stockOn the 14th of May, Håkan Johansson bought around 3k shares on-market at roughly kr70.00 per share. In the last 3 months, there was an even bigger purchase from another insider worth kr407k. Håkan has been a buyer over the last 12 months, purchasing a net total of kr434k worth in shares.Recent Insider Transactions • May 19Chief Financial Officer recently bought kr210k worth of stockOn the 14th of May, Håkan Johansson bought around 3k shares on-market at roughly kr70.00 per share. In the last 3 months, there was an even bigger purchase from another insider worth kr407k. Håkan has been a buyer over the last 12 months, purchasing a net total of kr434k worth in shares.Breakeven Date Change • May 17Forecast to breakeven in 2023The analyst covering Bonesupport Holding expects the company to break even for the first time. New forecast suggests losses will reduce by 60% per year to 2022. The company is expected to make a profit of kr54.0m in 2023. Average annual earnings growth of 92% is required to achieve expected profit on schedule.Recent Insider Transactions • May 16Chief Financial Officer recently bought kr210k worth of stockOn the 14th of May, Håkan Johansson bought around 3k shares on-market at roughly kr70.00 per share. In the last 3 months, there was an even bigger purchase from another insider worth kr407k. Håkan has been a buyer over the last 12 months, purchasing a net total of kr434k worth in shares.Reported Earnings • May 12First quarter 2021 earnings releasedThe company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: kr44.8m (up 3.2% from 1Q 2020). Net loss: kr20.2m (loss narrowed 31% from 1Q 2020).Reported Earnings • Apr 17Full year 2020 earnings released: kr1.72 loss per share (vs kr3.10 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: kr180.9m (up 16% from FY 2019). Net loss: kr101.4m (loss narrowed 37% from FY 2019).Reported Earnings • Feb 19Full year 2020 earnings released: kr1.72 loss per share (vs kr3.10 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: kr180.9m (up 16% from FY 2019). Net loss: kr101.4m (loss narrowed 37% from FY 2019).Analyst Estimate Surprise Post Earnings • Feb 19Revenue beats expectationsRevenue exceeded analyst estimates by 1.0%. Over the next year, revenue is forecast to grow 67%, compared to a 45% growth forecast for the Biotechs industry in the United Kingdom.Recent Insider Transactions • Jan 23Executive VP of R&D recently bought kr69k worth of stockOn the 14th of January, Michael Diefenbeck bought around 950 shares on-market at roughly kr72.73 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr121k more in shares than they have sold in the last 12 months.Recent Insider Transactions • Jan 17Executive VP of R&D recently bought kr69k worth of stockOn the 14th of January, Michael Diefenbeck bought around 950 shares on-market at roughly kr72.73 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr121k more in shares than they have sold in the last 12 months.Is New 90 Day High Low • Dec 29New 90-day high: kr77.00The company is up 21% from its price of kr63.40 on 30 September 2020. The British market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is kr2.12 per share.Is New 90 Day High Low • Dec 01New 90-day high: kr75.60The company is up 57% from its price of kr48.00 on 02 September 2020. The British market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.이익 및 매출 성장 예측BATS-CHIXE:BONEXS - 애널리스트 향후 추정치 및 과거 재무 데이터 (SEK Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20282,567727591605612/31/20271,983508389401612/31/20261,49630728029163/31/20261,215185244250N/A12/31/20251,175142216221N/A9/30/20251,119152235241N/A6/30/20251,062148207212N/A3/31/20259981229195N/A12/31/20248991346066N/A9/30/202481491-35N/A6/30/2024735289-29-21N/A3/31/202465626707N/A12/31/2023591245-24-18N/A9/30/2023522214-40-37N/A6/30/2023448-30-66-63N/A3/31/2023382-51-51-48N/A12/31/2022329-68-50-47N/A9/30/2022287-72-62-58N/A6/30/2022257-71-72-68N/A3/31/2022234-82-81-77N/A12/31/2021213-86-87-83N/A9/30/2021205-88-90-88N/A6/30/2021198-96-89-87N/A3/31/2021182-92-88-86N/A12/31/2020181-101-103-100N/A9/30/2020174-115-121-117N/A6/30/2020165-127-143-139N/A3/31/2020166-151-155-150N/A12/31/2019155-161N/A-164N/A9/30/2019132-166N/A-176N/A6/30/2019108-191N/A-189N/A3/31/201998-182N/A-177N/A12/31/201897-176N/A-172N/A9/30/2018101-182N/A-147N/A6/30/2018119-146N/A-128N/A3/31/2018128-132N/A-112N/A12/31/2017129-129N/A-108N/A9/30/2017132-112N/A-112N/A6/30/2017126-124N/A-106N/A3/31/2017114-124N/A-103N/A12/31/2016105-110N/A-82N/A12/31/201562-60N/A-65N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: BONEXS 의 연간 예상 수익 증가율(33.8%)이 saving rate(3.4%)보다 높습니다.수익 vs 시장: BONEXS 의 연간 수익(33.8%)이 UK 시장(11.4%)보다 빠르게 성장할 것으로 예상됩니다.고성장 수익: BONEXS 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.수익 대 시장: BONEXS 의 수익(연간 23.2%)이 UK 시장(연간 4.6%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: BONEXS 의 수익(연간 23.2%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: BONEXS의 자본 수익률은 3년 후 35.9%로 높을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/21 21:04종가2026/05/28 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Bonesupport Holding AB (publ)는 8명의 분석가가 다루고 있습니다. 이 중 6명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관null nullABG Sundal CollierErik CasselDanske BankKristofer Liljeberg-SvenssonDNB Carnegie5명의 분석가 더 보기
공시 • Jan 14Bonesupport Holding AB (Publ) Provides Earnings Guidance for the Fourth Quarter of 2025 and Full Year 2026Bonesupport Holding AB (publ) provided earnings guidance for the fourth quarter of 2025 and full year 2026. For the quarter, Net sales is expected to total 313 MSEK, representing 36.0% growth at constant exchange rates compared with the same period in 2024. For the year, the company expected sales growth above 35% at constant exchange rates.
공시 • Nov 29Bonesupport Holding AB Provides Sales Guidance for the Year 2024Bonesupport Holding AB provided sales guidance for the year 2024. For the year, the company expects sales growth to be above 40% (in constant currency).
Breakeven Date Change • Jun 02Forecast breakeven date moved forward to 2023The 2 analysts covering Bonesupport Holding previously expected the company to break even in 2024. New consensus forecast suggests the company will make a profit of kr15.7m in 2023. Earnings growth of 103% is required to achieve expected profit on schedule.
Breakeven Date Change • May 15Forecast breakeven date moved forward to 2023The 2 analysts covering Bonesupport Holding previously expected the company to break even in 2024. New consensus forecast suggests the company will make a profit of kr15.7m in 2023. Earnings growth of 103% is required to achieve expected profit on schedule.
Breakeven Date Change • Oct 25Forecast to breakeven in 2023The 2 analysts covering Bonesupport Holding expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 21% to 2022. The company is expected to make a profit of kr5.67m in 2023. Average annual earnings growth of 120% is required to achieve expected profit on schedule.
Breakeven Date Change • Jun 01Forecast breakeven date moved forward to 2023The 2 analysts covering Bonesupport Holding previously expected the company to break even in 2024. New consensus forecast suggests losses will reduce by 26% to 2022. The company is expected to make a profit of kr2.70m in 2023. Average annual earnings growth of 112% is required to achieve expected profit on schedule.
공시 • Jun 16Bonesupport Holding AB (publ) (OM:BONEX) commences an Equity Buyback Plan for own shares, under the authorization approved on May 12, 2026.Bonesupport Holding AB (publ) (OM:BONEX) commences share repurchases on June 9, 2026, under the program mandated by the shareholders in the Annual General Meeting held on May 12, 2026. As per the mandate, the company is authorized to repurchase own shares, representing does not exceed 10% of its issued share capital at any point of time. The shares will be repurchased at a price which falls within the prevailing price interval registered at each point in time (i.e. in the interval between the highest purchase price and the lowest selling price). The purpose of the proposed authorizations, and the reason for deviating from the shareholders' preferential rights with regard to transfer of own shares, is to enable acquisition financing through the utilization of own ordinary shares, to give the Board of Directors the opportunity to continuously adapt the company's capital structure to the company's capital needs and thereby contribute to increased shareholder value, and to give the company the opportunity to divest shares in its own holding for cash flow hedging of social security costs arising from the delivery of shares to participants in the incentive program resolved by the Annual General Meeting 2023 (LTI 2023).The ordinary shares shall be made in cash. The repurchased shares will be cancelled by resolution of upcoming Annual General Meetings. The program is valid until the next Annual General Meeting in 2027. On June 8, 2026, the company announced a share repurchase program. Under the program, the company will repurchase up to 373,320 shares for SEK 100 million. The ordinary shares shall be made in cash. The program will commence from June 9, 2026 and be valid till July 9, 2026.
Recent Insider Transactions • Jun 02Director recently bought kr200k worth of stockOn the 27th of May, Jens Viebke bought around 844 shares on-market at roughly kr237 per share. This transaction amounted to 39% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth kr346k. Despite this recent purchase, insiders have collectively sold kr6.4m more in shares than they bought in the last 12 months.
공시 • Jan 14Bonesupport Holding AB (Publ) Provides Earnings Guidance for the Fourth Quarter of 2025 and Full Year 2026Bonesupport Holding AB (publ) provided earnings guidance for the fourth quarter of 2025 and full year 2026. For the quarter, Net sales is expected to total 313 MSEK, representing 36.0% growth at constant exchange rates compared with the same period in 2024. For the year, the company expected sales growth above 35% at constant exchange rates.
공시 • Oct 23+ 3 more updatesBonesupport Holding AB (publ) to Report Q1, 2026 Results on Apr 22, 2026Bonesupport Holding AB (publ) announced that they will report Q1, 2026 results on Apr 22, 2026
공시 • Sep 16Bonesuport Announces Positive Results from A Clinical Study Demonstrating Significantly Improved Patient-Based Outcomes for Cerament®? G in Single-Stage Revision Surgery for Patients Patients Lining from Periprosthetic Joint InfectionBonesuport announced positive results from a clinical study demonstrating significantly improved patient-reported outcomes for CERAMENT®? G in single-stage revision surgery for patients suffering from periprosthetic joint infection (PJI) of the hip. The top-line results were presented at the European Bone and Joint Infection Society (EBJIS) annual meting, 11-13 September 2025. The prospective clinical study conducted at Charite - Universitatsmedizin Berlin, involved twenty patients with confirmed PJI of the hip. The procedure included implant removal, debridement (removal of infected tissue), and defect augmentation using CERAMENT G, followed by cementless revision arthroplasty in a single stage procedure. None of the patients experienced a re-infection during the 24-month follow-up period. Significant improvements were observed in patient-reported outcomes eg. the Harris Hip Score, EQ-5D-5L and Pain Visual Analogue Scale (VAS). According to the German Arthroplasty Registry (Endoprothesenregister Deutschland) the risk of reinfection is 30% within two years following hip revision surgery. The current standard of care remains a two-stage procedure, where the infection is treated in a primary surgery and the new prosthesis is implanted in a second surgery up to eight weeks later. The study (CeraHip) is expected to be published during the autumn.
공시 • Apr 24Bonesupport Holding AB (publ), Annual General Meeting, May 27, 2025Bonesupport Holding AB (publ), Annual General Meeting, May 27, 2025, at 10:00 W. Europe Standard Time. Location: to be held at elite hotel ideon, scheelevagen 27, lund Sweden
공시 • Apr 01Bonesupport Holding AB (Publ) Files FDA Submission for Cerament VBonesUPPORT announced that the company has submitted market authorization application for its antibiotic eluting bone graft substitute, CERAMENT® V (vancomycin), with the Food and Drug Administration (FDA), for the indication bone infection. The market approval for CERAMENT® G in 2022 was based on extensive efficacy and patient safety data, with nearly 17,000 clinical data points. The clinical data, from several published studies, demonstrated that CERAMENT G is superior to previous standard options in managing bone infections. With market authorization for CERAMENT V, physicians would be equipped with an additional tool to manage bone infections, primarily caused by Methicillin-Resistant Staphylococcus eg. MRSA or MRSE. CERAMENT V in Europe, where the product has had market approval for several years, represents 15% of the sales of antibiotic-releasing products. Bone grafts with local antibiotic release have proven to be a very important tool in the ambition to drastically reduce the need for systemic antibiotic use and combat antibiotic resistance. CERAMENT V has previously received the categorization of "breakthrough device" for the indication of bone infection from the FDA.
공시 • Jan 08Bonesupport Holding AB (publ) Announces Study Results for CERAMENT G and CERAMENT V in Surgical Treatment of Bone Infection Due to Diabetic Foot UlcersBonesupport Holding AB (publ) announced strong study results for CERAMENT G and CERAMENT V in the surgical treatment of bone infection due to diabetic foot ulcers. The study is the first to document that surgical treatment with antibiotic eluting CERAMENT has contributed to increased survival rates over a 5-year period. The published clinical study included 105 patients with diabetic foot osteomyelitis that were either treated with surgical conventional treatment or surgical treatment including CERAMENT G or CERAMENT V. The results regarding infection healing, residual infection, re-infection, amputation, and mortality all showed significant advantages for the antibiotic eluting CERAMENT compared to standard treatment. The pioneering finding of the study was the dramatic improvement in 5-year survival within the CERAMENT group: 87.5%, compared to 44.9% in the standard treatment group [Mortality rate 12,5%, versus 55.1%, p<0.00001].
공시 • Nov 29Bonesupport Holding AB (publ) Announces Nomination Committee ChangesThe composition of BONESUPPORT's Nomination Committee ahead of the 2025 Annual General Meeting was announced in the company's interim report for the third quarter on October 24 2024. As a result of a subsequent change in ownership, the composition of the Nomination Committee has changed with Anna Sundberg (appointed by Handelsbanken Fonder) leaving the Nomination Committee and Erik Selin (appointed by Erik Selin Fastigheter AB) joining as a new member of the Nomination Committee. Accordingly, the Nomination Committee ahead of the 2025 Annual General Meeting consists of the following members: Caroline Sjösten, appointed by Swedbank Robur Fonder; Erik Selin, appointed by Erik Selin Fastigheter; and Staffan Lindstrand, appointed by HealthCap. In addition, the Chairman of the Board of BONESUPPORT, Lennart Johansson, is co-opted to the Nomination Committee. The Nomination Committee has appointed Caroline Sjösten as Committee chair.
공시 • Oct 31Erik Selin acquired 5.92% stake in Bonesupport Holding AB (publ) (OM:BONEX) from Odlander, Fredrikson & Co. AB.Erik Selin acquired 5.92% stake in Bonesupport Holding AB (publ) (OM:BONEX) from Odlander, Fredrikson & Co. AB for SEK 1.3 billion on October 30, 2024. In this transaction, Erik Selin will acquire 3.9 million shares at a rate of SEK 325. Erik Selin acquired 5.92% stake in Bonesupport Holding AB (publ) (OM:BONEX) from Odlander, Fredrikson & Co. AB on October 30, 2024.
공시 • Oct 26+ 3 more updatesBonesupport Holding AB (publ) to Report Q2, 2025 Results on Jul 15, 2025Bonesupport Holding AB (publ) announced that they will report Q2, 2025 results on Jul 15, 2025
공시 • Jun 13+ 1 more updateBonesupport Holding AB (Publ) Appoints Anna Stegmark as EVP Quality Management & Regulatory Affairs, with Effect from 1 July 2024Bonesupport Holding AB (publ) announced that Anna Stegmark has been appointed EVP Quality Management & Regulatory Affairs with effect from 1 July 2024. She will also be part of the management team. Anna Stegmark's professional career comprises more than 19 years in the medical device sector, leading global quality and regulatory teams since 2010. Most recently, she was with Radiometer Medical as Director QA Operation.
Reported Earnings • Apr 23Full year 2023 earnings released: EPS: kr3.77 (vs kr1.06 loss in FY 2022)Full year 2023 results: EPS: kr3.77 (up from kr1.06 loss in FY 2022). Revenue: kr591.1m (up 80% from FY 2022). Net income: kr245.0m (up kr313.2m from FY 2022). Profit margin: 42% (up from net loss in FY 2022). The move to profitability was primarily driven by higher revenue. Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 24% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 89% per year but the company’s share price has only increased by 60% per year, which means it is significantly lagging earnings growth.
공시 • Feb 23Bonesupport Holding AB (Publ) Announces Resignation of Kristina Ingvar as Executive Vice President Quality Management & Regulatory AffairsBONESUPPORT AB announced a change in its management team. Kristina Ingvar will leave BONESUPPORT and her role as Executive Vice President Quality Management & Regulatory Affairs (EVP QM&RA). The change is effective as per 22 March 2024. She will take up a position as Corporate Vice President in the global healthcare company Novo Nordisk. Recruitment for the position EVP QM&RA has been initiated.
Reported Earnings • Feb 17Full year 2023 earnings released: EPS: kr3.77 (vs kr1.06 loss in FY 2022)Full year 2023 results: EPS: kr3.77 (up from kr1.06 loss in FY 2022). Revenue: kr591.1m (up 80% from FY 2022). Net income: kr245.0m (up kr313.2m from FY 2022). Profit margin: 42% (up from net loss in FY 2022). The move to profitability was primarily driven by higher revenue. Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 89% per year but the company’s share price has only increased by 37% per year, which means it is significantly lagging earnings growth.
공시 • Nov 29Bonesupport Holding AB Provides Sales Guidance for the Year 2024Bonesupport Holding AB provided sales guidance for the year 2024. For the year, the company expects sales growth to be above 40% (in constant currency).
공시 • Oct 27+ 4 more updatesBonesupport Holding AB (publ) to Report Q1, 2024 Results on Apr 25, 2024Bonesupport Holding AB (publ) announced that they will report Q1, 2024 results on Apr 25, 2024
공시 • Oct 17Bone Support Receives “Breakthrough Device Designation” for Cerament® V for the Indication of Bone InfectionBONESUPPORTTM announced that the company's antibiotic eluting product CERAMENT® V has received categorization as a "breakthrough device" for the indication bone infection by the American Food and Drug Administration (FDA). The categorization breakthrough device is assigned to products that are considered to provide a more effective treatment of severe medical conditions, where there is no comparable equivalent on the market. The categorization has been added to expedite the regulatory review of new medical devices and give patients faster access to new treatment options. CERAMENT® G has previously received breakthrough device designation for the indication's bone infection and trauma.
Recent Insider Transactions • Jul 17Insider recently bought kr426k worth of stockOn the 14th of July, Michael Mortensen bought around 3k shares on-market at roughly kr142 per share. This transaction amounted to 30% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth kr604k. Despite this recent purchase, insiders have collectively sold kr44m more in shares than they bought in the last 12 months.
Reported Earnings • Jul 14Second quarter 2023 earnings released: EPS: kr0.08 (vs kr0.25 loss in 2Q 2022)Second quarter 2023 results: EPS: kr0.08 (up from kr0.25 loss in 2Q 2022). Revenue: kr140.4m (up 88% from 2Q 2022). Net income: kr5.21m (up kr21.5m from 2Q 2022). Profit margin: 3.7% (up from net loss in 2Q 2022). The move to profitability was driven by higher revenue. Revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 36% per year whereas the company’s share price has increased by 39% per year.
Breakeven Date Change • Jun 02Forecast breakeven date moved forward to 2023The 2 analysts covering Bonesupport Holding previously expected the company to break even in 2024. New consensus forecast suggests the company will make a profit of kr15.7m in 2023. Earnings growth of 103% is required to achieve expected profit on schedule.
공시 • May 26BONESUPPORT Holding AB Announces Strong Long-Term Results with CERAMENT®G for Severe Open FracturesBONESUPPORT Holding AB announced the recent publication of long-term follow-up data demonstrating sustained high limb salvage rates and low deep infection rates with the company's antibiotic-eluting bone graft CERAMENT G. The study of 81 patients were managed with a single-stage procedure with CERAMENT G. Patients arrived at hospital with significant tissue loss and exposed bone tissue. With a mean follow-up of 55.8 months after surgery, it was found that 96.3% of patients had avoided an amputation, 96% had achieved bony union within 12 months, and 96.3% had avoided deep infection. The patients from the study were classified as having one of the most severe categories of open fractures (Gustilo-Anderson class IIIB), usually caused by traffic accidents. For this patient population, earlier publications have shown up to 16% amputation rates, non-unions up to 29%, and deep infection rates as high as 52%.
Recent Insider Transactions • May 18Insider recently sold kr701k worth of stockOn the 12th of May, Annelie Vikner sold around 7k shares on-market at roughly kr108 per share. This transaction amounted to 20% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth kr15m. Insiders have been net sellers, collectively disposing of kr43m more than they bought in the last 12 months.
Breakeven Date Change • May 15Forecast breakeven date moved forward to 2023The 2 analysts covering Bonesupport Holding previously expected the company to break even in 2024. New consensus forecast suggests the company will make a profit of kr15.7m in 2023. Earnings growth of 103% is required to achieve expected profit on schedule.
Recent Insider Transactions • May 05Chief Executive Officer recently sold kr15m worth of stockOn the 28th of April, Emil Billbäck sold around 146k shares on-market at roughly kr100 per share. This transaction amounted to 19% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Emil has been a net seller over the last 12 months, reducing personal holdings by kr21m.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Director Christine Rankin was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Apr 24Full year 2022 earnings released: kr1.06 loss per share (vs kr1.34 loss in FY 2021)Full year 2022 results: kr1.06 loss per share (improved from kr1.34 loss in FY 2021). Revenue: kr328.8m (up 55% from FY 2021). Net loss: kr68.2m (loss narrowed 20% from FY 2021). Revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 37% per year and the company’s share price has also increased by 37% per year.
Recent Insider Transactions • Mar 18Insider recently sold kr1.4m worth of stockOn the 14th of March, Fergus MacLeod sold around 17k shares on-market at roughly kr79.03 per share. This transaction amounted to 30% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of kr22m more than they bought in the last 12 months.
Reported Earnings • Feb 18Full year 2022 earnings released: kr1.06 loss per share (vs kr1.34 loss in FY 2021)Full year 2022 results: kr1.06 loss per share (improved from kr1.34 loss in FY 2021). Revenue: kr328.8m (up 55% from FY 2021). Net loss: kr68.2m (loss narrowed 20% from FY 2021). Revenue is forecast to grow 32% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 38% per year whereas the company’s share price has increased by 35% per year.
Board Change • Feb 09No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Director Christine Rankin was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Jan 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Director Christine Rankin was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Recent Insider Transactions • Jan 01Director recently bought kr203k worth of stockOn the 28th of December, Mary O’Connor bought around 3k shares on-market at roughly kr80.33 per share. This transaction amounted to 85% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold kr21m more in shares than they bought in the last 12 months.
Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Director Christine Rankin was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • Oct 30+ 2 more updatesBonesupport Holding AB (publ) to Report Q3, 2023 Results on Oct 26, 2023Bonesupport Holding AB (publ) announced that they will report Q3, 2023 results on Oct 26, 2023
Reported Earnings • Oct 28Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: kr84.6m (up 54% from 3Q 2021). Net loss: kr15.0m (loss widened 6.3% from 3Q 2021). Revenue is forecast to grow 36% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the United Kingdom.
Breakeven Date Change • Oct 25Forecast to breakeven in 2023The 2 analysts covering Bonesupport Holding expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 21% to 2022. The company is expected to make a profit of kr5.67m in 2023. Average annual earnings growth of 120% is required to achieve expected profit on schedule.
Board Change • Oct 03No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Director Christine Rankin was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Sep 13No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Director Christine Rankin was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Jul 29No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Director Christine Rankin was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Jul 15Second quarter 2022 earnings released: kr0.25 loss per share (vs kr0.42 loss in 2Q 2021)Second quarter 2022 results: kr0.25 loss per share (up from kr0.42 loss in 2Q 2021). Revenue: kr74.6m (up 44% from 2Q 2021). Net loss: kr16.3m (loss narrowed 40% from 2Q 2021). Over the next year, revenue is forecast to grow 37%, compared to a 11% growth forecast for the industry in the United Kingdom.
Recent Insider Transactions • Jun 14Insider recently bought kr101k worth of stockOn the 8th of June, Lars Lindgren bought around 2k shares on-market at roughly kr63.00 per share. In the last 3 months, there was an even bigger purchase from another insider worth kr1.2m. Insiders have collectively bought kr4.0m more in shares than they have sold in the last 12 months.
Breakeven Date Change • Jun 01Forecast breakeven date moved forward to 2023The 2 analysts covering Bonesupport Holding previously expected the company to break even in 2024. New consensus forecast suggests losses will reduce by 26% to 2022. The company is expected to make a profit of kr2.70m in 2023. Average annual earnings growth of 112% is required to achieve expected profit on schedule.
Board Change • May 31Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. 1 independent director (4 non-independent directors). Independent Director Tone Kvale was the last independent director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Breakeven Date Change • Feb 20Forecast breakeven date pushed back to 2024The 2 analysts covering Bonesupport Holding previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 34% per year to 2023. The company is expected to make a profit of kr135.5m in 2024. Average annual earnings growth of 71% is required to achieve expected profit on schedule.
Reported Earnings • Feb 18Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: kr1.31 loss per share (up from kr1.72 loss in FY 2020). Revenue: kr212.9m (up 18% from FY 2020). Net loss: kr85.5m (loss narrowed 16% from FY 2020). Revenue missed analyst estimates by 1.1%. Over the next year, revenue is forecast to grow 42%, compared to a 16% growth forecast for the pharmaceuticals industry in the United Kingdom.
Board Change • Feb 01Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. 1 independent director (4 non-independent directors). Independent Director Tone Kvale was the last independent director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Dec 15Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. 1 independent director (4 non-independent directors). Independent Director Tone Kvale was the last independent director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Nov 06Third quarter 2021 earnings releasedThe company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: kr54.9m (up 14% from 3Q 2020). Net loss: kr14.1m (loss narrowed 34% from 3Q 2020).
Breakeven Date Change • Nov 02Forecast to breakeven in 2023The 2 analysts covering Bonesupport Holding expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr83.0m in 2023. Average annual earnings growth of 72% is required to achieve expected profit on schedule.
Board Change • Nov 02Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Director Tone Kvale was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Recent Insider Transactions • Aug 14Chief Financial Officer recently bought kr87k worth of stockOn the 11th of August, Håkan Johansson bought around 1k shares on-market at roughly kr74.15 per share. In the last 3 months, there was an even bigger purchase from another insider worth kr1.6m. Håkan has been a buyer over the last 12 months, purchasing a net total of kr521k worth in shares.
Board Change • Aug 03Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Director Tone Kvale was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Recent Insider Transactions • Aug 03Executive VP of R&D recently sold kr595k worth of stockOn the 29th of July, Michael Diefenbeck sold around 8k shares on-market at roughly kr78.25 per share. This was the largest sale by an insider in the last 3 months. Despite this recent sale, insiders have collectively bought kr2.4m more than they sold in the last 12 months.
Recent Insider Transactions • May 22Chief Financial Officer recently bought kr210k worth of stockOn the 14th of May, Håkan Johansson bought around 3k shares on-market at roughly kr70.00 per share. In the last 3 months, there was an even bigger purchase from another insider worth kr407k. Håkan has been a buyer over the last 12 months, purchasing a net total of kr434k worth in shares.
Recent Insider Transactions • May 19Chief Financial Officer recently bought kr210k worth of stockOn the 14th of May, Håkan Johansson bought around 3k shares on-market at roughly kr70.00 per share. In the last 3 months, there was an even bigger purchase from another insider worth kr407k. Håkan has been a buyer over the last 12 months, purchasing a net total of kr434k worth in shares.
Breakeven Date Change • May 17Forecast to breakeven in 2023The analyst covering Bonesupport Holding expects the company to break even for the first time. New forecast suggests losses will reduce by 60% per year to 2022. The company is expected to make a profit of kr54.0m in 2023. Average annual earnings growth of 92% is required to achieve expected profit on schedule.
Recent Insider Transactions • May 16Chief Financial Officer recently bought kr210k worth of stockOn the 14th of May, Håkan Johansson bought around 3k shares on-market at roughly kr70.00 per share. In the last 3 months, there was an even bigger purchase from another insider worth kr407k. Håkan has been a buyer over the last 12 months, purchasing a net total of kr434k worth in shares.
Reported Earnings • May 12First quarter 2021 earnings releasedThe company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: kr44.8m (up 3.2% from 1Q 2020). Net loss: kr20.2m (loss narrowed 31% from 1Q 2020).
Reported Earnings • Apr 17Full year 2020 earnings released: kr1.72 loss per share (vs kr3.10 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: kr180.9m (up 16% from FY 2019). Net loss: kr101.4m (loss narrowed 37% from FY 2019).
Reported Earnings • Feb 19Full year 2020 earnings released: kr1.72 loss per share (vs kr3.10 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: kr180.9m (up 16% from FY 2019). Net loss: kr101.4m (loss narrowed 37% from FY 2019).
Analyst Estimate Surprise Post Earnings • Feb 19Revenue beats expectationsRevenue exceeded analyst estimates by 1.0%. Over the next year, revenue is forecast to grow 67%, compared to a 45% growth forecast for the Biotechs industry in the United Kingdom.
Recent Insider Transactions • Jan 23Executive VP of R&D recently bought kr69k worth of stockOn the 14th of January, Michael Diefenbeck bought around 950 shares on-market at roughly kr72.73 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr121k more in shares than they have sold in the last 12 months.
Recent Insider Transactions • Jan 17Executive VP of R&D recently bought kr69k worth of stockOn the 14th of January, Michael Diefenbeck bought around 950 shares on-market at roughly kr72.73 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr121k more in shares than they have sold in the last 12 months.
Is New 90 Day High Low • Dec 29New 90-day high: kr77.00The company is up 21% from its price of kr63.40 on 30 September 2020. The British market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is kr2.12 per share.
Is New 90 Day High Low • Dec 01New 90-day high: kr75.60The company is up 57% from its price of kr48.00 on 02 September 2020. The British market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.